Metropolis Healthcare gains 9% on market debut

The Rs 1,204 crore IPO, which was sold between April 3 to April 5, was subscribed 5.83 times.

View in App
Getty Images
At the issue price, the stock was valued at of 39 times FY19 annualised earnings against Dr Lal Pathlabs’ 43 times.
NEW DELHI: Metropolis Healthcare on Monday made a decent market debut, as the scrip got listed at Rs 960 on BSE, a 9.09 per cent premium over issue price of Rs 880 per share.

The scrip closed at Rs 959.55, up 9.04 per cent with respect to its issue price.

The Rs 1,204 crore IPO, which was sold between April 3 to April 5, was subscribed 5.83 times.


At the issue price, the stock was valued at of 39 times FY19 annualised earnings against Dr Lal Pathlabs’ 43 times.

Metropolis’ laboratory network consists of 115 clinical laboratories, comprising a global reference laboratory located in Mumbai, 14 regional reference laboratories 56 satellite laboratories and 44 express laboratories.

The diagnostic company, which offers approximately 3,487 clinical laboratory tests and 530 profiles, has presence across 19 states and a leadership position in West and South India through its network of 83 clinical laboratories, 1,473 patient touch points and 396 ARCs (assisted referral centres) in the regions.

The revenue from operations rose at a CAGR of 16.3 per cent to Rs 643.6 crore from FY16 to FY18, while profits climbed at a CAGR of 15.7 per cent to Rs 109.7 crore. The company is debt free.
ADVERTISEMENT

In nine months to December 31, 2018, the diagnostic company conducted 12.3 million tests on 6.6 million patients compared with 16 million tests on 7.7 million patients in in the entire FY18.
READ MORE
ADVERTISEMENT

READ MORE:

LOGIN & CLAIM

50 TIMESPOINTS

ET Business Listings
Generate Enquiries for your Business by Listing on Economictimes.com

More from our Partners

Loading next story
Text Size:AAA
save image

Success
This article has been saved

*